[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339252-105":3,"doc-detail-339252-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","wild-type-idh2-is-a-therapeutic-target-for-triple-negative-breast-cancer","Wild-type IDH2 is a therapeutic target for triple-negative breast cancer","","Wild-type IDH2 is shown to be highly expressed in triple-negative breast cancer (TNBC) cells, where it promotes proliferation in vitro and tumor growth in vivo. Genetic silencing or pharmacological inhibition of wt-IDH2 increases α-ketoglutarate (α-KG), suppressing the reductive TCA cycle and causing impaired mitochondrial ATP synthesis. This metabolic double-hit depletes ATP, suppresses glycolysis via HIF-1α degradation, and sensitizes TNBC cells to doxorubicin. The findings identify wt-IDH2 as a potential TNBC therapeutic target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/wild-type-idh2-is-a-therapeutic-target-for-triple-negative-breast-cancer/339252/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/wild-type-idh2-is-a-therapeutic-target-for-triple-negative-breast-cancer/339252.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does wild-type IDH2 play in triple-negative breast cancer?","Question",{"text":63,"@type":64},"Wild-type IDH2 is highly expressed in TNBC cells and promotes their proliferation in vitro and tumor growth in vivo.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does inhibiting or silencing wt-IDH2 affect cellular metabolism?",{"text":68,"@type":64},"Genetic silencing or pharmacological inhibition increases α-ketoglutarate (α-KG), indicating suppression of reductive TCA cycle activity, which abrogates mitochondrial ATP synthesis.",{"name":70,"@type":61,"acceptedAnswer":71},"Why might TNBC cells become more sensitive to doxorubicin after wt-IDH2 suppression?",{"text":72,"@type":64},"The resulting ATP depletion and suppression of tumor-supporting metabolic pathways (including glycolysis via HIF-1α degradation) weaken tumor cell fitness, increasing sensitivity to doxorubicin.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339252,1790693939,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45",8,"Article [https://doi.org/10.1038/s41467-024-47536-6](https://doi.org/10.1038/s41467-024-47536-6)  \nWild-type IDH2 is a therapeutic target for triple-negative breast cancer  \nReceived: 30 August 2020  \n\n| Accepted: 26 March 2024 |\n| --- |\n| |\n| Check for updates |\n\nJiang-jiang Li 1, Tiantian Yu 2, Peiting Zeng 1, Jingyu Tian1, Panpan Liu 1,3, Shuang Qiao 1, Shijun Wen 1, Yumin Hu 1, Qiao Liu1, Wenhua Lu1, Hui Zhang1,2 & Peng Huang 1,2   \nMutations in isocitrate dehydrogenases (IDH) are oncogenic events due to the generation of oncogenic metabolite 2-hydroxyglutarate. However, the role of wild-type IDH in cancer development remains elusive. Here we show that wildtype IDH2 is highly expressed in triple negative breast cancer (TNBC) cells and promotes their proliferation in vitro and tumor growth in vivo. Genetic silencing or pharmacological inhibition of wt-IDH2 causes a signiﬁcant increase in α-ketoglutarate (α-KG), indicating a suppression of reductive tricarboxylic acid (TCA) cycle. The aberrant accumulation of α-KG due to IDH2 abrogation inhibits mitochondrial ATP synthesis and promotes HIF-1α degradation, leading to suppression of glycolysis. Such metabolic double-hit results in ATP depletion and suppression of tumor growth, and renders TNBC cells more sensitive to doxorubicin treatment. Our study reveals a metabolic property of TNBC cells with active utilization of glutamine via reductive TCA metabolism, and suggests that wild-type IDH2 plays an important role in this metabolic process and could be a potential therapeutic target for TNBC.  \nMetabolic alterations are consistently observed in various types of cancer cells, and have been considered as a major hallmark of cancer1. The increase in aerobic glycolysis, known as the Warburg effect, represents a most well-studied metabolic phenomenon in cancer cells and constitutes a biochemical basis of the 18F-FDG PET-CT scan for cancer diagnosis due to the elevated uptake of glucose by cancer tissues2. The discovery that mutations in isocitrate dehydrogenases (IDH1 or IDH2) could drive cancer development due to the abnormal generation of an oncometabolite 2-hydroxyglutarate is another example of the direct involvement of altered metabolism in carcinogenesis. In fact, IDH1 and IDH2 mutations have been detected in a majority of low-grade gliomas and secondary high-grade gliomas3, and in approximately 20% of acute myeloid leukemia (AML)4. Mechanistically, IDH mutations lead to cancer development due in part to certain changes in epigenetics and redox signaling induced by  \n2-hydroxyglutarate accumulation5–7. The important role of IDH mutations in cancer is further underscored by the fact that IDH inhibitors such as Ivosidenib and Enasidenib have been developed for cancer treatment8.  \nDespite the long-standing observations of cancer metabolic reprogramming and its successful applications to cancer diagnosis, attempts to use metabolic intervention strategies for cancer treatment have so far been met with mixed results9. Although inhibition of glycolysis seems to be a logical approach to abrogating cancer metabolism and thus might selectively impact the malignant cells, so far, no clinically effective glycolytic inhibitors have been successfully developed for the treatment of cancer patients10. This is due in part to the high metabolic ﬂexibility of cancer cells, which are able to change their metabolic pathways in response to metabolic intervention11,12. For example, inhibition of glycolysis may induce a compensatory increase  \n1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center,651 Dongfeng East Road, Guangzhou 510060, China. 2Metabolic Innovation Center, Sun Yat-sen University Zhongshan School of Medicine, Guangzhou 510080, China. 3Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, China.  \ne-mail: [huangpeng@sysucc.org.cn](huangpeng@s","cbCaipvjVrIccUSu","https://ap.wps.com/l/cbCaipvjVrIccUSu","pdf",2369945,17,"English","# Background: cancer metabolism and IDH biology\n## Warburg effect and metabolic intervention challenges\n# IDH2 function and mechanistic framing\n## Oxidative vs reductive TCA cycle roles\n# Study findings in TNBC\n## wt-IDH2 expression and effects on proliferation and tumor growth\n## α-KG accumulation and ATP/glycolysis suppression\n## HIF-1α degradation and chemosensitivity","[{\"question\":\"What role does wild-type IDH2 play in triple-negative breast cancer?\",\"answer\":\"Wild-type IDH2 is highly expressed in TNBC cells and promotes their proliferation in vitro and tumor growth in vivo.\"},{\"question\":\"How does inhibiting or silencing wt-IDH2 affect cellular metabolism?\",\"answer\":\"Genetic silencing or pharmacological inhibition increases α-ketoglutarate (α-KG), indicating suppression of reductive TCA cycle activity, which abrogates mitochondrial ATP synthesis.\"},{\"question\":\"Why might TNBC cells become more sensitive to doxorubicin after wt-IDH2 suppression?\",\"answer\":\"The resulting ATP depletion and suppression of tumor-supporting metabolic pathways (including glycolysis via HIF-1α degradation) weaken tumor cell fitness, increasing sensitivity to doxorubicin.\"}]","Wild-type IDH2 is a therapeutic target for triple-negative breast cancer | PDF",1790028963,43,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f53428f1bc3262ebd79cd8d8559fe32.webp",983,1305,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b372d25d5d6f521fba61219753d41389.webp",982,1304,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80c4975815048b84a1b2be7a034a8189.webp",981,1303,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94743d51809e3f336294504e523524c5.webp",980,1301,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]